Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 22, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Volume | Price (GBP) | Transaction Type |
|---|---|---|---|---|
| May 19, 2017 | Ordinary Shares (25p) | 16,065 | 16.4227 | Sale |
| May 19, 2017 | Ordinary Shares (25p) | 7,435 | 16.4153 | Sale |
Material Changes
The filing reports no material changes to the company's business operations or financial position. It discloses two separate sales of ordinary shares executed on the London Stock Exchange on May 19, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of insider trading activity.
Key Facts for Investor Verification
- Insider Sales: Mr. R G Connor (President, Global Manufacturing & Supply) sold 16,065 shares.
- Associated Person Sales: Mrs. D Connor (PCA of Mr. Connor) sold 7,435 shares.
- Total Volume: A combined total of 23,500 ordinary shares were sold by these parties.
- Transaction Venue: Transactions occurred on the London Stock Exchange (XLON).
- Price Range: Shares were sold at approximately £16.42 per share.